Welcome to our dedicated page for Cormedix news (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on Cormedix stock.
Cormedix Inc (CRMD) is a clinical-stage biopharmaceutical company pioneering novel therapies for life-threatening infectious and inflammatory conditions. This news hub provides investors and healthcare stakeholders with essential updates on DefenCath developments, regulatory milestones, and therapeutic pipeline progress.
Access timely announcements including FDA correspondence, clinical trial data, and commercialization strategies for CRMD's catheter lock solutions. Our curated collection features earnings reports, partnership disclosures, and scientific presentations relevant to infection prevention in critical care settings.
Key updates cover therapeutic candidate advancements, intellectual property developments, and market expansion initiatives. Monitor progress in addressing bloodstream infections through CRMD's specialized antimicrobial formulations designed for high-risk patient populations.
Bookmark this page for structured access to verified corporate communications and analysis of how CRMD navigates the complex biopharmaceutical regulatory landscape. Stay informed on developments impacting both patient care standards and long-term therapeutic innovation.
CorMedix (NASDAQ: CRMD) reports strong preliminary Q1 2025 results with unaudited net revenue of $39.0 million and expected adjusted EBITDA exceeding $22.5 million. The company's cash position stands at $77.5 million as of March 31, 2025.
Due to larger than anticipated orders in late March and improved visibility into customer inventory levels, CorMedix has raised its H1 2025 net sales guidance to $62-70 million. While Q2 2025 sales are expected to be lower than Q1 due to shipment timing, patient utilization is forecast to grow throughout 2025, with H2 shipments projected to exceed H1.
The company plans to begin patient enrollment for DefenCath's Phase 3 study in Total Parenteral Nutrition (TPN) patients in late April. If approved, DefenCath's peak annual sales potential in this indication is estimated at $150-200 million, with a total addressable market of $500-750 million.
CorMedix (Nasdaq: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The event will be held virtually from April 7-10, 2025.
The company's management will engage in a Fireside Chat scheduled for Tuesday, April 8, 2025, at 2:15 p.m. EDT. This participation aligns with CorMedix's ongoing efforts to maintain investor relations and industry presence.
CorMedix (NASDAQ: CRMD) reported strong financial results for Q4 and full year 2024, marking its first profitable commercial quarter. The company achieved Q4 net revenue of $31.2 million and full-year revenue of $43.5 million, primarily driven by DefenCath sales since its outpatient launch in July 2024.
Q4 highlights include net income of $13.5 million and adjusted EBITDA of $15.3 million. The company ended 2024 with $51.7 million in cash and short-term investments. CorMedix provided preliminary guidance for H1 2025 with expected net revenue of $50-60 million, including over $33 million in Q1.
Key developments include partnering with Syneos Health for inpatient sales team building and WSI for VA facilities marketing. The company is preparing to commence a Phase 3 study of DefenCath in Total Parenteral Nutrition patients in Q2 2025, with a pending FDA Orphan Drug Status application.
CorMedix (Nasdaq: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has scheduled its Q4 and Full Year 2024 financial results announcement. The company will release its financial performance report before market opens on March 25, 2025, followed by a corporate update conference call at 8:30am Eastern Time.
CorMedix (Nasdaq: CRMD), a biopharmaceutical company, has announced a collaboration with WSI PBG, a subsidiary of Golden State Medical Supply, to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs (VA) and other federal facilities.
This partnership aims to enhance access to critical therapies for approximately 40,000 veterans living with end-stage renal disease (ESRD) and other beneficiaries of federal programs. WSI PBG will leverage its expertise in navigating VA and federal facilities, including access, procurement processes, and regulations, to meet the unique needs of these healthcare systems.
CorMedix and WSI PBG are committed to improving health outcomes by providing increased access to DefenCath for patients at VA and other federal facilities. Joe Todisco, CEO of CorMedix, expressed excitement about the collaboration, citing WSI PBG's deep understanding of the federal healthcare landscape as a key factor in enhancing access to DefenCath and ensuring equitable care for veterans and other federal healthcare beneficiaries.
CorMedix (NASDAQ: CRMD) reports strong preliminary Q4 2024 results with unaudited net revenue of approximately $31 million and full-year 2024 revenue of $43 million. Q4 adjusted EBITDA is expected to exceed $12 million, achieving the company's breakeven target by year-end 2024.
The company has secured over $25 million in open purchase orders for Q1 2025 delivery and is actively shipping DefenCath to three midsized dialysis operators. CorMedix plans to expand into the inpatient hospital segment in Q1 2025 through a partnership with Syneos Health for dedicated sales team deployment. The company projects FY 2025 operating expenses of $72-78 million, with increased R&D spending for clinical initiatives.
As of December 31, 2024, CorMedix maintains a strong financial position with approximately $52 million in cash and short-term investments.
CorMedix Inc. (CRMD) has announced its upcoming addition to the Nasdaq Biotechnology Index (NBI), effective before market open on Monday, December 23, 2024. The NBI is a modified market capitalization weighted index tracking NASDAQ-listed biotechnology and pharmaceutical companies. Inclusion in the index is based on specific eligibility criteria, including minimum market capitalization and average daily trading volume requirements. The index undergoes annual reconstitution in December.
CorMedix welcomes significant CMS policy updates that will enhance hemodialysis patients' access to innovative therapies. Starting January 2025, CMMI's Kidney Care Choices model will exclude TDAPA payments from financial calculations, facilitating access to new drugs including DefenCath®. This change affects over 30% of ESRD patients in the US currently enrolled in KCC programs, removing financial barriers to innovative drug utilization and ensuring patient care choices aren't by cost considerations.
CorMedix (Nasdaq: CRMD) announced its participation in the Truist Securities BioPharma Symposium scheduled for November 7, 2024, in New York City. The event will feature one-on-one meetings at the Lotte New York Palace Hotel. CorMedix is focused on commercializing DefenCath®, their lead product approved by the FDA in November 2023. The company has already launched DefenCath in inpatient settings in April 2024 and expanded to outpatient settings in July 2024. They plan to further develop DefenCath as a catheter lock solution for additional patient populations.
CorMedix reported Q3 2024 financial results with net revenue of $11.5 million in its first full quarter of DefenCath sales. The company secured commercial agreements covering approximately 60% of US outpatient dialysis centers. Net loss decreased to $2.8 million ($0.05 per share) compared to $9.7 million ($0.17 per share) in Q3 2023. Operating expenses increased 34% to $14.1 million. Cash position stands at $46.0 million, which the company believes is sufficient for at least twelve months of operations. CorMedix is preparing to expand DefenCath indications beyond adult hemodialysis with several clinical initiatives planned for early 2025.
FAQ
What is the current stock price of Cormedix (CRMD)?
What is the market cap of Cormedix (CRMD)?
